DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION Take orally with or without food, at any time of day. (2.1)Assess LDL-C when clinically appropriate, as early as weeks after initiating CRESTOR, and adjust dosage if necessary. (2.1)Adults: Recommended dosage range is to 40 mg once daily. (2.2)Pediatric Patients with HeFH: Recommended dosage range is to 10 mg once daily for patients aged to less than 10 years of age, and to 20 mg once daily for patients aged 10 years and older. (2.3)Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged years and older. (2.3)Asian Patients: Initiate at mg once daily. Consider risks and benefits of treatment if not adequately controlled at dosages up to 20 mg once daily. (2.4)Patients with Severe Renal Impairment (not on hemodialysis): Initiate at mg once daily; do not exceed 10 mg once daily. (2.5)See full prescribing information for CRESTOR dosage and administration modifications due to drug interactions. (2.6). 2.1 General Dosage and Administration Information. oAdminister CRESTOR orally as single dose at any time of day, with or without food. Swallow the tablets whole.oAssess LDL-C when clinically appropriate, as early as weeks after initiating CRESTOR, and adjust the dosage if necessary.oIf dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.oWhen taking CRESTOR with an aluminum and magnesium hydroxide combination antacid, administer CRESTOR at least hours before the antacid [see Drug Interactions (7.2)].. oAdminister CRESTOR orally as single dose at any time of day, with or without food. Swallow the tablets whole.. oAssess LDL-C when clinically appropriate, as early as weeks after initiating CRESTOR, and adjust the dosage if necessary.. oIf dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.. oWhen taking CRESTOR with an aluminum and magnesium hydroxide combination antacid, administer CRESTOR at least hours before the antacid [see Drug Interactions (7.2)].. 2.2 Recommended Dosage in Adult Patients. oThe dosage range for CRESTOR is to 40 mg orally once daily.oThe recommended dosage of CRESTOR depends on patients indication for usage, LDL-C, and individual risk for CV events.. oThe dosage range for CRESTOR is to 40 mg orally once daily.. oThe recommended dosage of CRESTOR depends on patients indication for usage, LDL-C, and individual risk for CV events.. 2.3 Recommended Dosage in Pediatric Patients. Dosage in Pediatric Patients Years of Age and Older with HeFHThe recommended dosage range is mg to 10 mg orally once daily in patients aged years to less than 10 years and mg to 20 mg orally once daily in patients aged 10-years and older.Dosage in Pediatric Patients Years of Age and Older with HoFHThe recommended dosage is 20 mg orally once daily.. 2.4 Recommended Dosage in Asian Patients. Initiate CRESTOR at mg orally once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of CRESTOR when treating Asian patients not adequately controlled at dosages up to 20 mg orally once daily [see Warnings and Precautions (5.1), Use in Specific Populations (8.8), and Clinical Pharmacology (12.3)].. 2.5 Recommended Dosage in Patients with Renal Impairment. In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m2) not on hemodialysis, the recommended starting dosage is mg orally once daily and should not exceed 10 mg orally once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.. 2.6 Dosage Modifications Due to Drug Interactions Table displays dosage modifications for CRESTOR due to drug interactions [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].Table 1: CRESTOR Dosage Modifications Due to Drug InteractionsConcomitantly Used DrugCRESTOR Dosage Modifications Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvirAvoid concomitant use. GemfibrozilAvoid concomitant use. If use is unavoidable, initiate at mg once daily and do not exceed 10 mg once daily. TafamidisAvoid concomitant use. If use is unavoidable, initiate at mg once daily and do not exceed 20 mg once daily. BelumosudilDo not exceed mg once daily. CyclosporineDo not exceed mg once daily. DarolutamideDo not exceed mg once daily. Additional Antiviral MedicationsSimeprevirDasabuvir/ombitasvir/paritaprevir/ritonavirElbasvir/GrazoprevirSofosbuvir/VelpatasvirGlecaprevir/PibrentasvirAtazanavir/Ritonavir Lopinavir/RitonavirInitiate at mg once daily. Do not exceed 10 mg once daily. CapmatinibDo not exceed 10 mg once daily. EnasidenibDo not exceed 10 mg once daily. MomelotinibDo not exceed 10 mg once daily. Regorafenib Do not exceed 10 mg once daily. TeriflunomideDo not exceed 10 mg once daily. TicagrelorDo not exceed 20 mg once daily. In patients at increased risk for rhabdomyolysis [see Warnings and Precautions (5.1)], consider dosages less than 20 mg per day. FebuxostatDo not exceed 20 mg once daily. FostamatinibDo not exceed 20 mg once daily.. Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvir. Gemfibrozil. Tafamidis. Belumosudil. Cyclosporine. Darolutamide. Additional Antiviral Medications. Simeprevir. Dasabuvir/ombitasvir/paritaprevir/ritonavir. Elbasvir/Grazoprevir. Sofosbuvir/Velpatasvir. Glecaprevir/Pibrentasvir. Atazanavir/Ritonavir Lopinavir/Ritonavir. Capmatinib. Enasidenib. Momelotinib. Regorafenib Teriflunomide. Ticagrelor. Febuxostat. Fostamatinib.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling:Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1)] Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2)] Hepatic Dysfunction [see Warnings and Precautions (5.3)] Proteinuria and Hematuria [see Warnings and Precautions (5.4)] Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.5)] Most frequent adverse reactions (rate >=2%) are headache, nausea, myalgia, asthenia, and constipation. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.Adverse reactions reported in >=2% of patients in placebo-controlled clinical studies and at rate greater than placebo are shown in Table 2. These studies had treatment duration of up to 12 weeks.Table 2: Adverse Reactions Reported in >=2% of Patients Treated with CRESTOR and Placebo in Placebo-Controlled TrialsAdverse ReactionsPlaceboN=382%CRESTOR5 mgN=291%CRESTOR10 mgN=283%CRESTOR20 mgN=64%CRESTOR40 mgN=106%TotalCRESTOR5 mg-40 mg N=744%Headache5.05.54.93.18.55.5Nausea3.13.83.56.303.4Myalgia1.33.12.16.31.92.8Asthenia2.62.43.24.70.92.7Constipation2.42.12.14.72.82.4Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.In the METEOR study, patients were treated with CRESTOR 40 mg (n=700) or placebo (n=281) with mean treatment duration of 1.7 years. Adverse reactions reported in >=2% of patients and at rate greater than placebo are shown in Table 3.Table 3: Adverse Reactions Reported in >=2% of Patients Treated with CRESTOR and Placebo in the METEOR TrialAdverse ReactionsPlacebo N=281%CRESTOR 40 mg N=700%Myalgia 12.112.7Arthralgia7.110.1Headache5.36.4Dizziness2.84.0Increased CPK0.72.6Abdominal pain1.82.4ALT greater than 3x ULNFrequency recorded as abnormal laboratory value. 0.72.2In the JUPITER study, patients were treated with CRESTOR 20 mg (n=8,901) or placebo (n=8,901) for mean duration of years. In JUPITER, there was significantly higher frequency of diabetes mellitus reported in patients taking CRESTOR (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in CRESTOR-treated patients compared to placebo-treated patients. The number of patients with HbA1c >6.5% at the end of the trial was significantly higher in CRESTOR-treated versus placebo-treated patients [see Clinical Studies (14)].Adverse reactions reported in >=2% of patients and at rate greater than placebo are shown in Table 4.Table 4: Adverse Reactions Reported in >=2% of Patients Treated with CRESTOR and Placebo in the JUPITER TrialAdverse ReactionsPlaceboN=8901%CRESTOR 20 mgN=8901%Myalgia6.67.6Arthralgia3.23.8Constipation3.03.3Diabetes mellitus2.32.8Nausea2.32.4Pediatric Patients with HeFHIn 12-week controlled study in pediatric patients 10 to 17 years of age with HeFH with CRESTOR mg to 20 mg daily [see Use in Specific Populations (8.4) and Clinical Studies (14)], elevations in serum CK greater than 10 ULN were observed more frequently in CRESTOR-treated patients compared with patients receiving placebo. Four of 130 (3%) patients treated with CRESTOR (2 treated with 10 mg and treated with 20 mg) had increased CK greater than 10 ULN, compared to of 46 patients on placebo.. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of CRESTOR. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.Blood Disorders: thrombocytopeniaHepatobiliary Disorders: hepatitis, jaundice, fatal and non-fatal hepatic failureMusculoskeletal Disorders: arthralgia, rare reports of immune-mediated necrotizing myopathy associated with statin useNervous System Disorders: peripheral neuropathy, rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with the use of all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of weeks). There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or different statin was administered.Psychiatric Disorders: depression, sleep disorders (including insomnia and nightmares)Reproductive System and Breast Disorders: gynecomastiaRespiratory Disorders: interstitial lung diseaseSkin and Subcutaneous Tissue Disorders: drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action CRESTOR is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme to mevalonate, precursor of cholesterol.. 12.2 Pharmacodynamics Inhibition of HMG-CoA reductase by rosuvastatin accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of CRESTOR is usually achieved by weeks and is maintained after that.. 12.3 Pharmacokinetics AbsorptionIn clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached to hours following oral dosing. Both Cmax and AUC increased in approximate proportion to CRESTOR dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration.Effect of foodAdministration of CRESTOR with food did not affect the AUC of rosuvastatin.DistributionMean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.EliminationMetabolismRosuvastatin is not extensively metabolized; approximately 10% of radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.ExcretionFollowing oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours.Specific PopulationsGeriatric PatientsThere were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age >=65 years).Pediatric PatientsIn population pharmacokinetic analysis of two pediatric trials involving patients with HeFH 10 to 17 years of age and to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients.Male and Female PatientsThere were no differences in plasma concentrations of rosuvastatin between males and females.Racial or Ethnic GroupsA population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among White, Hispanic or Latino ethnicity, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate fold elevation in median exposure (AUC and Cmax) in Asian subjects when compared with White control group.Patients with Renal ImpairmentMild to moderate renal impairment (CLcr >=30 mL/min/1.73 m2) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to clinically significant extent (about 3-fold) in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not receiving hemodialysis compared with healthy subjects (CLcr >80 mL/min/1.73 m2).Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.Patients with Hepatic ImpairmentIn patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.In patients with Child-Pugh disease, Cmax and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh disease, Cmax and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.Drug Interactions StudiesRosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to clinically significant extent.Rosuvastatin is substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of CRESTOR with medications that are inhibitors of these transporter proteins (e.g., cyclosporine, certain HIV protease inhibitors [see Dosage and Administration (2.6) and Drug Interactions (7.1)] and ticagrelor [see Drug Interactions (7.1)]) may result in increased rosuvastatin plasma concentrations.Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic ExposureCoadministered drug and dosing regimenRosuvastatinMean Ratio (ratio with/without coadministered drug) No Effect=1.0Dosage (mg)1Change in AUCChange in Cmax Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg) Voxilaprevir (100 mg) once daily for 15 days10 mg, single dose7.39(6.68 to 8.18) 18.88(16.23 to 21.96) Cyclosporine stable dose required (75 mg 200 mg BID)10 mg, QD for 10 days7.111Darolutamide 600 mg BID, days5 mg, single dose5.22 ~52 Belumosudil 200 mg QD, days10 mg, single dose on separate days4.623.59Regorafenib 160 mg QD, 14 days5 mg, single dose3.84.6Enasidenib 100 mg QD, 28 days10 mg, single dose3.44.66Atazanavir/ritonavir combination 300 mg/100 mg QD for days10 mg3.17Simeprevir 150 mg QD, days10 mg, single dose2.82 (2.3 to 3.4)3 3.2(2.6 to 3.9)3 Momelotinib 200 mg OD, days10 mg, single dose2.73.2Velpatasvir 100 mg once daily10 mg, single dose2.692 (2.46 to 2.94) 2.61(2.32 to 2.92)3 Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg dasabuvir 400 mg BID5 mg, single dose2.59(2.09 to 3.21) 7.13(5.11 to 9.96)3 TeriflunomideNot available2.512.65Ticagrelor 90 mg BID10 mg, single dose 20 mg, single dose2.32.32.42.6Elbasvir 50 mg/grazoprevir 200 mg once daily10 mg, single dose2.26(1.89 to 2.69) 5.49(4.29 to 7.04)3 Glecaprevir 400 mg/pibrentasvir 120 mg once daily5 mg, once daily2.15(1.88 to 2.46) 5.62(4.80 to 6.59)3 Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days20 mg, QD for days2.1(1.7 to 2.6)3 5to3 Capmatinib 400 mg BID10 mg, single dose2.08(1.56 to 2.76) 3.04(2.36 to 3.92)3 Fostamatinib 100 mg BID20 mg, single dose1.96(1.77 to 2.15) 1.88(1.69 to 2.09) Febuxostat 120 mg QD for days10 mg, single dose1.9(1.5 to 2.5) 2.1(1.8 to 2.6)3 Gemfibrozil 600 mg BID for days80 mg1.9to 2.2to3 Tafamidis 61 mg BID on Days & 2, followed by QD on Days to 910 mg1.972 (1.68 to 2.31)3 1.862 (1.59 to 2.16)3 Eltrombopag 75 mg QD, days10 mg1.6(1.4 to 1.7)3 2(1.8 to 2.3)3 Darunavir 600 mg/ritonavir 100 mg BID, days10 mg, QD for days1.5(1.0 to 2.1)3 2.4(1.6 to 3.6)3 Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days10 mg1.4(1.2 to 1.6)3 2.2(1.8 to 2.7)3 Dronedarone 400 mg BID10 mg1.4Itraconazole 200 mg QD, days10 mg or 80 mg1.4(1.2 to 1.6)3 1.3(1.1 to 1.4)3 1.4(1.2 to 1.5)3 1.2(0.9 to 1.4)3 Ezetimibe 10 mg QD, 14 days10 mg, QD for 14 days1.2(0.9 to 1.6)3 1.2(0.8 to 1.6)3 Fosamprenavir/ritonavir 700 mg/100 mg BID for days 10 mg1.11.5Fenofibrate 67 mg TID for days10 mg<->1.2(1.1 to 1.3)3 Rifampicin 450 mg QD, days20 mg<->Aluminum magnesium hydroxide combination antacidAdministered simultaneouslyAdministered hours apart40 mg40 mg0.5to30.8(0.7 to 0.9)3 0.530.8(0.7 to 1.0)3 Ketoconazole 200 mg BID for days80 mg1.0(0.8 to 1.2)3 1.0(0.7 to 1.3)3 Fluconazole 200 mg QD for 11 days80 mg1.1(1.0 to 1.3)3 1.1(0.9 to 1.4)3 Erythromycin 500 mg QID for days80 mg0.8(0.7 to 0.9)3 0.7(0.5 to 0.9)3 Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other DrugsRosuvastatin Dosage RegimenCoadministered DrugMean Ratio (ratio with/without coadministered drug) No Effect=1.0 Name and DosageChange in AUCChange in Cmax 40 mg QD for 10 daysWarfarin25 mg single dose R- Warfarin1.0(1.0 to 1.1)2 S-Warfarin 1.1(1.0 to 1.1)2 R-Warfarin1.0(0.9 to 1.0)2 S-Warfarin 1.0(0.9 to 1.1)2 40 mg QD for 12 daysDigoxin 0.5 mg single dose1.0(0.9 to 1.2)2 1.0(0.9 to 1.2)2 40 mg QD for 28 daysOral Contraceptive(ethinyl estradiol 0.035 mg norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 DaysEE 1.3(1.2 to 1.3)2 NG 1.3(1.3 to 1.4)2 EE 1.3(1.2 to 1.3)2 NG 1.2(1.1 to 1.3)2 EE ethinyl estradiol, NG norgestrel, QD= Once daily. 12.5 Pharmacogenomics Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 (SLCO1B1 521T C). The frequency of this genotype (i.e., SLCO1B1 521 C/C) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of CRESTOR has not been clearly established.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES Primary Prevention of CV DiseaseIn the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of CRESTOR on the occurrence of major CV disease events was assessed in 17,802 males (>=50 years) and females (>=60 years) who had no clinically evident CV disease, LDL-C levels <130 mg/dL and hsCRP levels >=2 mg/L. The study population had an estimated baseline coronary heart disease risk of 11.6% over 10 years based on the Framingham risk criteria and included high percentage of patients with additional risk factors such as hypertension (58%), low HDL-C levels (23%), cigarette smoking (16%), or family history of premature CHD (12%). Patients had median baseline LDL-C of 108 mg/dL and hsCRP of 4.3 mg/L. Patients were randomly assigned to placebo (n=8901) or CRESTOR 20 mg once daily (n=8901) and were followed for mean duration of years. The JUPITER study was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in CRESTOR-treated subjects.The primary end point was composite end point consisting of the time-to-first occurrence of any of the following major CV events: CV death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or an arterial revascularization procedure.CRESTOR significantly reduced the risk of major CV events (252 events in the placebo group vs. 142 events in the rosuvastatin group) with statistically significant (p<0.001) relative risk reduction of 44% and absolute risk reduction of 1.2% (see Figure 1). The risk reduction for the primary end point was consistent across the following predefined subgroups: age, sex, race, smoking status, family history of premature CHD, body mass index, LDL-C, HDL-C, and hsCRP levels.Figure 1. Time to First Occurrence of Major CV Events in JUPITERThe individual components of the primary end point are presented in Figure 3. CRESTOR significantly reduced the risk of nonfatal myocardial infarction, nonfatal stroke, and arterial revascularization procedures. There were no significant treatment differences between the CRESTOR and placebo groups for death due to CV causes or hospitalizations for unstable angina.CRESTOR significantly reduced the risk of myocardial infarction (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. fatal events and 22 nonfatal events in CRESTOR-treated subjects) and the risk of stroke (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. fatal events and 30 nonfatal events in CRESTOR-treated subjects).In post-hoc subgroup analysis of JUPITER subjects (rosuvastatin=725, placebo=680) with hsCRP >=2 mg/L and no other traditional risk factors (smoking, BP >=140/90 or taking antihypertensives, low HDL-C) other than age, after adjustment for high HDL-C, there was no significant treatment benefit with CRESTOR treatment.Figure 2. Major CV Events by Treatment Group in JUPITERAt one year, CRESTOR increased HDL-C and reduced LDL-C, hsCRP, total cholesterol and serum triglyceride levels (p<0.001 for all versus placebo).Primary Hypercholesterolemia in AdultsCRESTOR reduces Total-C, LDL-C, ApoB, non-HDL-C, and TG, and increases HDL-C, in adult patients with Hypercholesterolemia and mixed dyslipidemia.In multicenter, double-blind, placebo-controlled study in patients with Hypercholesterolemia, CRESTOR given as single daily dose (5 to 40 mg) for weeks significantly reduced Total-C, LDL-C, non-HDL-C, and ApoB, across the dose range (Table 10).Table 10: Lipid-Modifying Effect of CRESTOR in Adult Patients with Hypercholesterolemia (Adjusted Mean Change from Baseline at Week 6)DoseNTotal-C LDL-C Non-HDL-C ApoBTGHDL-C Placebo13-5-7-7-3-33CRESTOR mg17-33-45-44-38-3513CRESTOR 10 mg17-36-52-48-42-1014CRESTOR 20 mg17-40-55-51-46-238CRESTOR 40 mg18-46-63-60-54-2810CRESTOR was compared with the statins (atorvastatin, simvastatin, and pravastatin) in multicenter, open-label, dose-ranging study of 2,240 patients with Hypercholesterolemia or mixed dyslipidemia. After randomization, patients were treated for weeks with single daily dose of either CRESTOR, atorvastatin, simvastatin, or pravastatin (see Figure and Table 11).Figure 3. Percent LDL-C Change by Dose of CRESTOR, Atorvastatin, Simvastatin, and Pravastatin at Week in Adult Patients with Hypercholesterolemia or Mixed Dyslipidemia Box plots are representation of the 25th, 50th, and 75th percentile values, with whiskers representing the 10th and 90th percentile values. Mean baseline LDL-C: 189 mg/dL.Table 11: Percent Change in LDL-C by Dose of CRESTOR, Atorvastatin, Simvastatin, and Pravastatin From Baseline to Week (LS MeanCorresponding standard errors are approximately 1.00.) in Adult Patients with Hypercholesterolemia or Mixed Dyslipidemia (Sample Sizes Ranging from 156-167 Patients Per Group)Treatment Daily DoseTreatment10 mg20 mg40 mg80 mgCRESTOR-46CRESTOR 10 mg reduced LDL-C significantly more than atorvastatin 10 mg; pravastatin 10 mg, 20 mg, and 40 mg; simvastatin 10 mg, 20 mg, and 40 mg. (p<0.002) -52CRESTOR 20 mg reduced LDL-C significantly more than atorvastatin 20 mg and 40 mg; pravastatin 20 mg and 40 mg; simvastatin 20 mg, 40 mg, and 80 mg. (p<0.002) -55CRESTOR 40 mg reduced LDL-C significantly more than atorvastatin 40 mg; pravastatin 40 mg; simvastatin 40 mg, and 80 mg. (p<0.002) ---Atorvastatin-37-43-48-51Simvastatin-28-35-39-46Pravastatin-20-24-30---Slowing of the Progression of AtherosclerosisIn the Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR) study, the effect of therapy with CRESTOR on carotid atherosclerosis was assessed by B-mode ultrasonography in patients with elevated LDL-C, at low risk (Framingham risk <10% over ten years) for symptomatic coronary artery disease and with subclinical atherosclerosis as evidenced by carotid intimal-medial thickness (cIMT). In this double-blind, placebo-controlled clinical study 984 adult patients were randomized (of whom 876 were analyzed) in 5:2 ratio to CRESTOR 40 mg or placebo once daily. Ultrasonograms of the carotid walls were used to determine the annualized rate of change per patient from baseline to two years in mean maximum cIMT of 12 measured segments. The estimated difference in the rate of change in the maximum cIMT analyzed over all 12 carotid artery sites between patients treated with CRESTOR and placebo-treated patients was -0.0145 mm/year (95% CI -0.0196, -0.0093; p<0.0001).The annualized rate of change from baseline for the placebo group was +0.0131 mm/year (p<0.0001). The annualized rate of change from baseline for the group treated with CRESTOR was -0.0014 mm/year (p=0.32).At an individual patient level in the group treated with CRESTOR, 52.1% of patients demonstrated an absence of disease progression (defined as negative annualized rate of change), compared to 37.7% of patients in the placebo group.HeFH in AdultsIn study of adult patients with HeFH (baseline mean LDL of 291 mg/dL), patients were randomized to CRESTOR 20 mg or atorvastatin 20 mg. The dose was increased at 6-week intervals. Significant LDL-C reductions from baseline were seen at each dose in both treatment groups (see Table 12).Table 12: LDL-C Percent Change from BaselineCRESTOR (n=435)LS MeanLS Means are least square means adjusted for baseline LDL-C (95% CI)Atorvastatin (n=187) LS Mean1 (95% CI)Week 620 mg-47% (-49%, -46%)-38% (-40%, -36%)Week 1240 mg-55% (-57%, -54%)-47% (-49%, -45%)Week 1880 mgNA-52% (-54%, -50%)HeFH in Pediatric PatientsIn double-blind, randomized, multicenter, placebo-controlled, 12-week study, 176 (97 male and 79 female) pediatric patients with HeFH were randomized to rosuvastatin mg, 10 mg or 20 mg or placebo daily. Patients ranged in age from 10 to 17 years (median age of 14 years) with approximately 30% of the patients 10 to 13 years and approximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at least 1-year postmenarche. Mean LDL-C at baseline was 233 mg/dL (range of 129 to 399). The 12-week double-blind phase was followed by 40-week open-label dose-titration phase, where all patients (n=173) received mg, 10 mg or 20 mg rosuvastatin daily.Rosuvastatin significantly reduced LDL-C (primary end point), total cholesterol and ApoB levels at each dose compared to placebo. Results are shown in Table 13 below.Table 13: Lipid-Modifying Effects of CRESTOR in Pediatric Patients 10 to 17 years of Age with HeFH (Least-Squares Mean Percent Change from Baseline To Week 12)Dose (mg)NLDL-C HDL-C Total-C TGMedian percent changeApoBPlacebo46-1%+7%0%-7%-2%542-38%+4%Difference from placebo not statistically significant -30%-13% -32%1044-45%+11% -34%-15% -38%2044-50%+9% -39%16% -41%Rosuvastatin was also studied in two-year open-label, uncontrolled, titration-to-goal trial that included 175 pediatric patients with HeFH who were to 17 years old (79 males and 96 females). All patients had documented genetic defect in the LDL receptor or in ApoB. Approximately 89% were White, 7% were Asian, 1% were Black or African American, and fewer than 1% were Hispanic or Latino ethnicity. Mean LDL-C at baseline was 236 mg/dL. Fifty-eight (33%) patients were prepubertal at baseline. The starting rosuvastatin dosage for all pediatric patients was mg once daily. Pediatric patients aged to less than 10 years (n=41 at baseline) could titrate to maximum dosage of 10 mg once daily, and pediatric patients aged 10 to 17 years could titrate to maximum dosage of 20 mg once daily.The reductions in LDL-C from baseline were generally consistent across age groups within the trial as well as with previous experience in both adult and pediatric controlled trials.HoFH in Adult and Pediatric PatientsIn an open-label, forced-titration study, HoFH patients (n=40, to 63 years) were evaluated for their response to CRESTOR 20 to 40 mg titrated at 6-week interval. In the overall population, the mean LDL-C reduction from baseline was 22%. About one-third of the patients benefited from increasing their dose from 20 mg to 40 mg with further LDL-C lowering of greater than 6%. In the 27 patients with at least 15% reduction in LDL-C, the mean LDL-C reduction was 30% (median 28% reduction). Among 13 patients with an LDL-C reduction of <15%, had no change or an increase in LDL-C. Reductions in LDL-C of 15% or greater were observed in of patients with known receptor negative status.HoFH in Pediatric PatientsCRESTOR was studied in randomized, double-blind, placebo-controlled, multicenter, cross-over study in 14 pediatric patients with HoFH. The study included 4-week dietary lead-in phase during which patients received CRESTOR 10 mg daily, cross-over phase that included two 6-week treatment periods with either CRESTOR 20 mg or placebo in random order, followed by 12-week open-label phase during which all patients received CRESTOR 20 mg. Patients ranged in age from to 15 years of age (median 11 years), 50% were male, 71% were White, 21% were Asian, 7% were Black or African American, and no patients were of Hispanic or Latino ethnicity. Fifty percent were on apheresis therapy and 57% were taking ezetimibe. Patients who entered the study on apheresis therapy or ezetimibe continued the treatment throughout the entire study. Mean LDL-C at baseline was 416 mg/dL (range 152 to 716 mg/dL). total of 13 patients completed both treatment periods of the randomized cross-over phase; one patient withdrew consent due to inability to have blood drawn during the cross-over phase.CRESTOR 20 mg significantly reduced LDL-C, total cholesterol, ApoB, and non-HDL-C compared to placebo (see Table 14).Table 14: Lipid-Modifying Effects of CRESTOR in Pediatric Patients to 15 years of Age with HoFH After WeeksPlacebo(N=13)CRESTOR 20 mg(N=13)Percent difference (95% CI)LDL-C (mg/dL)481396-22.3% (-33.5, -9.1)p=0.005 Total-C (mg/dL)539448-20.1% (-29.7, -9.1)p=0.003 Non-HDL-C (mg/dL)505412-22.9% (-33.7, -10.3) ApoB (mg/dL)268235-17.1% (-29.2, -2.9) p=0.024 Difference estimates are based on transformations of the estimated mean difference in log LDL measurements between CRESTOR and placebo using mixed model adjusted for study period.Primary Dysbetalipoproteinemia in AdultsIn randomized, multicenter, double-blind crossover-study, 32 adult patients (27 with 2/2 and with apo mutation [Arg145Cys] with primary dysbetalipoproteinemia entered 6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to sequence of treatments for weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10 mg. CRESTOR reduced non-HDL-C (primary end point) and circulating remnant lipoprotein levels. Results are shown in the table below.Table 15: Lipid-Modifying Effects of CRESTOR 10 mg and 20 mg in Adult Patients with Primary Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent Change (95% CI) from Baseline (N=32)Median at Baseline (mg/dL)Median percent change from baseline (95% CI)CRESTOR 10 mgMedian percent change from baseline (95% CI)CRESTOR 20 mgTotal-C342.5-43.3(-46.9, 37.5)-47.6(-51.6,-42.8)Triglycerides503.5-40.1(-44.9, -33.6)-43.0(-52.5, -33.1)Non-HDL-C294.5-48.2(-56.7, -45.6)-56.4(-61.4, -48.5)VLDL-C IDL-C209.5-46.8(-53.7, -39.4)-56.2(-67.7, -43.7)LDL-C112.5-54.4(-59.1, -47.3)-57.3(-59.4, -52.1)HDL-C35.510.2(1.9, 12.3)11.2(8.3, 20.5)RLP-C82.0-56.4(-67.1, -49.0)-64.9(-74.0, -56.6)Apo-E16.0-42.9(-46.3, -33.3)-42.5(-47.1, -35.6)Hypertriglyceridemia in AdultsIn double-blind, placebo-controlled study in adult patients with baseline TG levels from 273 to 817 mg/dL, CRESTOR given as single daily dose (5 to 40 mg) over weeks significantly reduced serum TG levels (Table 16).Table 16: Lipid-Modifying Effect of CRESTOR in Adult Patients with Primary Hypertriglyceridemia After Six Weeks by Median (Min, Max) Percent Change from Baseline to Week 6DosePlacebo (n=26)CRESTOR mg(n=25)CRESTOR 10 mg (n=23)CRESTOR 20 mg (n=27)CRESTOR 40 mg (n=25)Triglycerides1 (-40, 72)-21 (-58, 38)-37 (-65, 5)-37 (-72, 11)-43 (-80, -7)Non-HDL-C2 (-13, 19)-29 (-43, -8)-49 (-59, -20)-43 (-74, 12)-51 (-62, -6)Total-C1 (-13, 17)-24 (-40, -4)-40 (-51, -14)-34 (-61, -11)-40 (-51, -4)LDL-C5 (-30, 52)-28 (-71, 2)-45 (-59, 7)-31 (-66, 34)-43 (-61, -3)HDL-C-3 (-25, 18)3 (-38, 33)8 (-8, 24)22 (-5, 50)17 (-14, 63). figure1timejupiter. figure2-majorjupiter. figure3percentdyslipidemia.

DRUG INTERACTIONS SECTION.

7 DRUG INTERACTIONS See full prescribing information for details regarding concomitant use of CRESTOR with other drugs that increase the risk of myopathy and rhabdomyolysis. (7.1)Aluminum and Magnesium Hydroxide Combination Antacids: Administer CRESTOR at least hours before the antacid. (7.2)Warfarin: Obtain INR prior to starting CRESTOR. Monitor INR frequently until stable upon initiation, dosage titration or discontinuation. (7.3). 7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with CRESTOR Rosuvastatin is substrate of CYP2C9 and transporters (such as OATP1B1, BCRP). Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table includes list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with CRESTOR and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].Table 5: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with CRESTORSofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvirPrevention or Management:Avoid concomitant use with CRESTOR.Mechanism and Clinical Effect(s):Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis. GemfibrozilPrevention or Management:Avoid concomitant use of gemfibrozil with CRESTOR. If use is unavoidable, initiate CRESTOR at mg once daily and do not exceed dosage of CRESTOR 10 mg once daily. Mechanism and Clinical Effect(s):Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use.TafamidisPrevention or Management:Avoid concomitant use of tafamidis with CRESTOR. If use is unavoidable, initiate CRESTOR at mg once daily and do not exceed dosage of CRESTOR 20 mg once daily. Monitor for signs of myopathy and rhabdomyolysis if used concomitantly with CRESTOR. Mechanism and Clinical Effect(s):Tafamidis significantly increased rosuvastatin exposure and tafamidis may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use.BelumosudilPrevention or Management:In patients taking belumosudil, do not exceed dosage of CRESTOR mg once daily. Mechanism and Clinical Effect(s):Belumosudil increased rosuvastatin exposure more than 4.6-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.CyclosporinePrevention or Management:In patients taking cyclosporine, do not exceed dosage of CRESTOR mg once daily.Mechanism and Clinical Effect(s):Cyclosporine increased rosuvastatin exposure 7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.DarolutamidePrevention or Management:In patients taking darolutamide, do not exceed dosage of CRESTOR mg once daily. Mechanism and Clinical Effect(s):Darolutamide increased rosuvastatin exposure more than 5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. Additional Anti-Viral MedicationsPrevention or Management:oSimeprevir oDasabuvir/ombitasvir/paritaprevir/ritonavir oElbasvir/grazoprevir oSofosbuvir/velpatasvir oGlecaprevir/pibrentasvir oAtazanavir/ritonaviroLopinavir/ritonavir Initiate with CRESTOR mg once daily, and do not exceed dosage of CRESTOR 10 mg once daily. Mechanism and Clinical Effect(s):Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis. CapmatinibPrevention or Management:In patients taking capmatinib, do not exceed dosage of CRESTOR 10 mg once daily. Mechanism and Clinical Effect(s):Capmatinib increased rosuvastatin exposure more than 2.1-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.EnasidenibPrevention or Management:In patients taking enasidenib, do not exceed dosage of CRESTOR 10 mg once daily. Mechanism and Clinical Effect(s):Enasidenib increased rosuvastatin exposure more than 3.4-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.MomelotinibPrevention or Management:In patients taking momelotinib, do not exceed dosage of CRESTOR 10 mg once daily.Mechanism and Clinical Effect(s):Momelotinib increased rosuvastatin exposure by 2.7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.RegorafenibPrevention or Management:In patients taking regorafenib, do not exceed dosage of CRESTOR 10 mg once daily. Mechanism and Clinical Effect(s):Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy and rhabdomyolysis.TeriflunomidePrevention or Management:In patients taking teriflunomide, do not exceed dosage of CRESTOR 10 mg once daily. Mechanism and Clinical Effect(s):Teriflunomide increased rosuvastatin exposure more than 2.5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.TicagrelorPrevention or Management:In patients taking ticagrelor, do not exceed dosage of CRESTOR 20 mg once daily. In patients at increased risk for rhabdomyolysis [see Warnings and Precautions (5.1)], consider dosages less than 20 mg per day.Mechanism and Clinical Effect(s):Ticagrelor increased rosuvastatin exposure by 2.3-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.FebuxostatPrevention or Management:In patients taking febuxostat, do not exceed dosage of CRESTOR 20 mg once daily. Mechanism and Clinical Effect(s):Febuxostat increased rosuvastatin exposure more than 1.9-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.FostamatinibPrevention or Management:In patients taking fostamatinib, do not exceed dosage of CRESTOR 20 mg once daily. Mechanism and Clinical Effect(s):Fostamatinib increased rosuvastatin exposure more than 2.0-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.Fenofibrates (e.g., fenofibrate and fenofibric acid)Prevention or Management:Consider if the benefit of using fibrates concomitantly with CRESTOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of either drug.Mechanism and Clinical Effect(s):Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use. ColchicinePrevention or Management:Consider if the benefit of using colchicine concomitantly with CRESTOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of either drug.Mechanism and Clinical Effect(s):Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with CRESTOR.NiacinPrevention or Management:Consider if the benefit of using lipid-modifying dosages (>=1 g/day) of niacin concomitantly with CRESTOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of either drug.Mechanism and Clinical Effect(s):Cases of myopathy and rhabdomyolysis have occurred with concomitant use of lipid-modifying dosages (>=1 g/day) of niacin with CRESTOR.. oSimeprevir oDasabuvir/ombitasvir/paritaprevir/ritonavir oElbasvir/grazoprevir oSofosbuvir/velpatasvir oGlecaprevir/pibrentasvir oAtazanavir/ritonavir. oLopinavir/ritonavir 7.2 Drug Interactions that Decrease the Efficacy of CRESTOR Table presents drug interactions that may decrease the efficacy of CRESTOR and instructions for preventing or managing them.Table 6: Drug Interactions that Decrease the Efficacy of CRESTOR AntacidsPrevention or Management:In patients taking an antacid, administer CRESTOR at least hours before the antacid. Mechanism and Clinical Effect(s):Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% [see Clinical Pharmacology (12.3)]. Antacids. 7.3 CRESTOR Effects on Other Drugs Table presents CRESTORs effect on other drugs and instructions for preventing or managing them.Table 7: CRESTOR Effects on Other Drugs Warfarin Prevention or Management:In patients taking warfarin, obtain an INR before starting CRESTOR and frequently enough after initiation, dosage titration or discontinuation to ensure that no significant alteration in INR occurs. Once the INR is stable, monitor INR at regularly recommended intervals.Mechanism and Clinical Effect(s):Rosuvastatin significantly increased the INR in patients receiving warfarin [see Clinical Pharmacology (12.3)]. Warfarin.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE CRESTOR is indicated:oTo reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events.oAs an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C):in adults with hypercholesterolemia.and slow the progression of atherosclerosis in adults.in adults and pediatric patients aged years and older with heterozygous familial hypercholesterolemia (HeFH).in adults and pediatric patients aged years and older with homozygous familial hypercholesterolemia (HoFH).oAs an adjunct to diet for the treatment of adults with:Primary dysbetalipoproteinemia.Hypertriglyceridemia.. oTo reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events.. oAs an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C):in adults with hypercholesterolemia.and slow the progression of atherosclerosis in adults.in adults and pediatric patients aged years and older with heterozygous familial hypercholesterolemia (HeFH).in adults and pediatric patients aged years and older with homozygous familial hypercholesterolemia (HoFH).. in adults with hypercholesterolemia.. and slow the progression of atherosclerosis in adults.. in adults and pediatric patients aged years and older with heterozygous familial hypercholesterolemia (HeFH).. in adults and pediatric patients aged years and older with homozygous familial hypercholesterolemia (HoFH).. oAs an adjunct to diet for the treatment of adults with:Primary dysbetalipoproteinemia.Hypertriglyceridemia.. Primary dysbetalipoproteinemia.. Hypertriglyceridemia.. CRESTOR is an HMG Co-A reductase inhibitor (statin) indicated: (1)oTo reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events.oAs an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): in adults with primary hypercholesterolemia.and slow the progression of atherosclerosis in adults.in adults and pediatric patients aged years and older with heterozygous familial hypercholesterolemia (HeFH).in adults and pediatric patients aged years and older with homozygous familial hypercholesterolemia (HoFH).oAs an adjunct to diet for the treatment of adults with:Primary dysbetalipoproteinemia.Hypertriglyceridemia.. oTo reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events.. oAs an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): in adults with primary hypercholesterolemia.and slow the progression of atherosclerosis in adults.in adults and pediatric patients aged years and older with heterozygous familial hypercholesterolemia (HeFH).in adults and pediatric patients aged years and older with homozygous familial hypercholesterolemia (HoFH).. in adults with primary hypercholesterolemia.. and slow the progression of atherosclerosis in adults.. in adults and pediatric patients aged years and older with heterozygous familial hypercholesterolemia (HeFH).. in adults and pediatric patients aged years and older with homozygous familial hypercholesterolemia (HoFH).. oAs an adjunct to diet for the treatment of adults with:Primary dysbetalipoproteinemia.Hypertriglyceridemia.. Primary dysbetalipoproteinemia.. Hypertriglyceridemia.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics AbsorptionIn clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached to hours following oral dosing. Both Cmax and AUC increased in approximate proportion to CRESTOR dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration.Effect of foodAdministration of CRESTOR with food did not affect the AUC of rosuvastatin.DistributionMean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.EliminationMetabolismRosuvastatin is not extensively metabolized; approximately 10% of radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.ExcretionFollowing oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours.Specific PopulationsGeriatric PatientsThere were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age >=65 years).Pediatric PatientsIn population pharmacokinetic analysis of two pediatric trials involving patients with HeFH 10 to 17 years of age and to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients.Male and Female PatientsThere were no differences in plasma concentrations of rosuvastatin between males and females.Racial or Ethnic GroupsA population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among White, Hispanic or Latino ethnicity, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate fold elevation in median exposure (AUC and Cmax) in Asian subjects when compared with White control group.Patients with Renal ImpairmentMild to moderate renal impairment (CLcr >=30 mL/min/1.73 m2) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to clinically significant extent (about 3-fold) in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not receiving hemodialysis compared with healthy subjects (CLcr >80 mL/min/1.73 m2).Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.Patients with Hepatic ImpairmentIn patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.In patients with Child-Pugh disease, Cmax and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh disease, Cmax and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.Drug Interactions StudiesRosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to clinically significant extent.Rosuvastatin is substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of CRESTOR with medications that are inhibitors of these transporter proteins (e.g., cyclosporine, certain HIV protease inhibitors [see Dosage and Administration (2.6) and Drug Interactions (7.1)] and ticagrelor [see Drug Interactions (7.1)]) may result in increased rosuvastatin plasma concentrations.Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic ExposureCoadministered drug and dosing regimenRosuvastatinMean Ratio (ratio with/without coadministered drug) No Effect=1.0Dosage (mg)1Change in AUCChange in Cmax Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg) Voxilaprevir (100 mg) once daily for 15 days10 mg, single dose7.39(6.68 to 8.18) 18.88(16.23 to 21.96) Cyclosporine stable dose required (75 mg 200 mg BID)10 mg, QD for 10 days7.111Darolutamide 600 mg BID, days5 mg, single dose5.22 ~52 Belumosudil 200 mg QD, days10 mg, single dose on separate days4.623.59Regorafenib 160 mg QD, 14 days5 mg, single dose3.84.6Enasidenib 100 mg QD, 28 days10 mg, single dose3.44.66Atazanavir/ritonavir combination 300 mg/100 mg QD for days10 mg3.17Simeprevir 150 mg QD, days10 mg, single dose2.82 (2.3 to 3.4)3 3.2(2.6 to 3.9)3 Momelotinib 200 mg OD, days10 mg, single dose2.73.2Velpatasvir 100 mg once daily10 mg, single dose2.692 (2.46 to 2.94) 2.61(2.32 to 2.92)3 Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg dasabuvir 400 mg BID5 mg, single dose2.59(2.09 to 3.21) 7.13(5.11 to 9.96)3 TeriflunomideNot available2.512.65Ticagrelor 90 mg BID10 mg, single dose 20 mg, single dose2.32.32.42.6Elbasvir 50 mg/grazoprevir 200 mg once daily10 mg, single dose2.26(1.89 to 2.69) 5.49(4.29 to 7.04)3 Glecaprevir 400 mg/pibrentasvir 120 mg once daily5 mg, once daily2.15(1.88 to 2.46) 5.62(4.80 to 6.59)3 Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days20 mg, QD for days2.1(1.7 to 2.6)3 5to3 Capmatinib 400 mg BID10 mg, single dose2.08(1.56 to 2.76) 3.04(2.36 to 3.92)3 Fostamatinib 100 mg BID20 mg, single dose1.96(1.77 to 2.15) 1.88(1.69 to 2.09) Febuxostat 120 mg QD for days10 mg, single dose1.9(1.5 to 2.5) 2.1(1.8 to 2.6)3 Gemfibrozil 600 mg BID for days80 mg1.9to 2.2to3 Tafamidis 61 mg BID on Days & 2, followed by QD on Days to 910 mg1.972 (1.68 to 2.31)3 1.862 (1.59 to 2.16)3 Eltrombopag 75 mg QD, days10 mg1.6(1.4 to 1.7)3 2(1.8 to 2.3)3 Darunavir 600 mg/ritonavir 100 mg BID, days10 mg, QD for days1.5(1.0 to 2.1)3 2.4(1.6 to 3.6)3 Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days10 mg1.4(1.2 to 1.6)3 2.2(1.8 to 2.7)3 Dronedarone 400 mg BID10 mg1.4Itraconazole 200 mg QD, days10 mg or 80 mg1.4(1.2 to 1.6)3 1.3(1.1 to 1.4)3 1.4(1.2 to 1.5)3 1.2(0.9 to 1.4)3 Ezetimibe 10 mg QD, 14 days10 mg, QD for 14 days1.2(0.9 to 1.6)3 1.2(0.8 to 1.6)3 Fosamprenavir/ritonavir 700 mg/100 mg BID for days 10 mg1.11.5Fenofibrate 67 mg TID for days10 mg<->1.2(1.1 to 1.3)3 Rifampicin 450 mg QD, days20 mg<->Aluminum magnesium hydroxide combination antacidAdministered simultaneouslyAdministered hours apart40 mg40 mg0.5to30.8(0.7 to 0.9)3 0.530.8(0.7 to 1.0)3 Ketoconazole 200 mg BID for days80 mg1.0(0.8 to 1.2)3 1.0(0.7 to 1.3)3 Fluconazole 200 mg QD for 11 days80 mg1.1(1.0 to 1.3)3 1.1(0.9 to 1.4)3 Erythromycin 500 mg QID for days80 mg0.8(0.7 to 0.9)3 0.7(0.5 to 0.9)3 Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other DrugsRosuvastatin Dosage RegimenCoadministered DrugMean Ratio (ratio with/without coadministered drug) No Effect=1.0 Name and DosageChange in AUCChange in Cmax 40 mg QD for 10 daysWarfarin25 mg single dose R- Warfarin1.0(1.0 to 1.1)2 S-Warfarin 1.1(1.0 to 1.1)2 R-Warfarin1.0(0.9 to 1.0)2 S-Warfarin 1.0(0.9 to 1.1)2 40 mg QD for 12 daysDigoxin 0.5 mg single dose1.0(0.9 to 1.2)2 1.0(0.9 to 1.2)2 40 mg QD for 28 daysOral Contraceptive(ethinyl estradiol 0.035 mg norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 DaysEE 1.3(1.2 to 1.3)2 NG 1.3(1.3 to 1.4)2 EE 1.3(1.2 to 1.3)2 NG 1.2(1.1 to 1.3)2 EE ethinyl estradiol, NG norgestrel, QD= Once daily.

PREGNANCY SECTION.

8.1 Pregnancy Risk SummaryDiscontinue CRESTOR when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient.CRESTOR decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, CRESTOR may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. In addition, treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia for most patients.Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with CRESTOR use in pregnant women are insufficient to determine if there is drug-associated risk of miscarriage (see Data).In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m2), respectively (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.DataHuman DataA Medicaid cohort linkage study of 1,152 statin-exposed pregnant women compared to 886,996 controls did not find significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of statin, and lack of information on non-live births.Animal DataIn female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD of 40 mg/day based on AUC).In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area).In pregnant rabbits given 0.3, 1, and mg/kg/day of rosuvastatin from gestation day to day 18, decreased fetal viability and maternal mortality was observed at mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after single oral gavage dose of mg/kg on gestation day 18.

SPL PATIENT PACKAGE INSERT SECTION.

PATIENT INFORMATIONCRESTOR(R) (Kres-tor)rosuvastatintablets, for oral useRead this Patient Information carefully before you start taking CRESTOR and each time you get refill. If you have any questions about CRESTOR, ask your healthcare provider. Only your healthcare provider can determine if CRESTOR is right for you.What is CRESTORCRESTOR is prescription medicine that contains cholesterol-lowering medicine called rosuvastatin.oCRESTOR is used:to reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or the need for procedures to improve blood flow to the heart called arterial revascularization, in adults at increased risk for these events.along with diet and exercise to lower the level of low-density lipoprotein (LDL-C) cholesterol or bad cholesterol:in adults with primary hypercholesterolemia.and slow the buildup of fatty deposits (plaque) in the walls of blood vessels in adults.in adults and children years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of LDL-C).in adults and children years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C). along with diet for the treatment of adults with:primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat).hypertriglyceridemia.It is not known if CRESTOR is safe and effective in children younger than years of age with HeFH or children younger than years of age with HoFH or in children with other types of hypercholesterolemias (other than HeFH or HoFH).Do not take CRESTOR if you:ohave liver problems.oare allergic to rosuvastatin or any of the ingredients in CRESTOR. See the end of this leaflet for complete list of ingredients in CRESTOR.Before you take CRESTOR, tell your healthcare provider about all of your medical conditions, including if you:ohave unexplained muscle aches or weakness.ohave or have had kidney problems.ohave or have had liver problems.odrink more than glasses of alcohol daily.ohave thyroid problems.oare of Asian descent.oare pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking CRESTOR, call your healthcare provider right away to discuss your CRESTOR treatment.oare breastfeeding. CRESTOR can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take CRESTOR. Do not breastfeed while taking CRESTOR.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider who prescribes CRESTOR if another healthcare provider increases the dose of another medicine you are taking. CRESTOR may affect the way other medicines work, and other medicines may affect how CRESTOR works.Especially tell your healthcare provider if you take:ocoumarin anticoagulants (medicines that prevent blood clots, such as warfarin)oantacids (medicines you take for heartburn that contain aluminum and magnesium hydroxideTaking CRESTOR with certain medicines may increase the risk of muscle problems. Especially tell your healthcare provider if you take:ocyclosporine (a medicine for your immune system)oteriflunomide (a medicine used to treat relapsing remitting multiple sclerosis)oenasidenib (a medicine used to treat acute myeloid leukemia)ocapmatinib (a medicine for the treatment of non-small cell lung cancer)ofostamatinib (a medicine used to treat low platelet counts) ofebuxostat (a medicine used to treat and prevent high blood levels of uric acid) ogemfibrozil (a fibric acid medicine for lowering cholesterol)otafamidis [used to treat cardiomyopathy (enlarged and thickened heart muscle)]oanti-viral medicines including certain HIV or hepatitis virus drugs such as:lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevircombination ofsofosbuvir/velpatasvir/voxilaprevirdasabuvir/ombitasvir/paritaprevir/ritonavirelbasvir/grazoprevirsofosbuvir/velpatasvirglecaprevir/pibrentasvir andall other combinations with ledipasvir including ledipasvir/sofosbuvir odarolutamide (a medicine for the treatment of prostate cancer)oregorafenib (a medicine used to treat cancer of the colon and rectum)ofibric acid derivatives (such as fenofibrate)oticagrelor (helps reduce the chance of blood clot formation that can block blood vessel)oniacin or nicotinic acidocolchicine (a medicine used to treat gout)obelumosudil (used to treat chronic graft-versus-host disease)omomelotinib (used to treat myelofibrosis, rare form of blood cancer)Ask your healthcare provider or pharmacist for list of these medicines if you are not sure. Know the medicines you take. Keep list of them to show your healthcare provider and pharmacist when you get new medicine.How should take CRESTORoTake CRESTOR exactly as your healthcare provider tells you to take it.oTake CRESTOR, by mouth, time each day, with or without food. Swallow the tablet whole.oCRESTOR can be taken at any time of day, with or without food.oDo not change your dose or stop CRESTOR without talking to your healthcare provider, even if you are feeling well.oYour healthcare provider may do blood tests to check your cholesterol levels before and during your treatment with CRESTOR. Your healthcare provider may change your dose of CRESTOR if needed.oWhile taking CRESTOR, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to.oIf you take medicine called an antacid that contains combination of aluminum and magnesium hydroxide, take CRESTOR at least hours before you take the antacid.oIf you miss dose of CRESTOR, take your next dose at your normal scheduled time. Do not take an extra dose of CRESTOR.oIn case of an overdose, get medical help or contact live Poison Center expert right away at 1-800-222-1222. Advice is also available online at poisonhelp.org.What are the possible side effects of CRESTORCRESTOR may cause serious side effects, including:oMuscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your healthcare provider right away if:you have unexplained muscle pain, tenderness, or weakness, especially if you have fever or feel more tired than usual, while you take CRESTOR.you have muscle problems that do not go away even after your healthcare provider has told you to stop taking CRESTOR. Your healthcare provider may do further tests to diagnose the cause of your muscle problems. Your chances of getting muscle problems are higher if you: are taking certain other medicines while you take CRESTOR (see Especially tell your healthcare provider if you take)are 65 years of age or olderare of Asian descenthave thyroid problems (hypothyroidism) that are not controlledhave kidney problemsare taking higher doses of CRESTORoLiver problems. Your healthcare provider may do blood tests to check your liver before you start taking CRESTOR and if you have symptoms of liver problems while you take CRESTOR. Call your healthcare provider right away if you have any of the following symptoms of liver problems:feel unusually tired or weakloss of appetiteupper belly paindark urineyellowing of your skin or the whites of your eyes oProtein and blood in the urine. CRESTOR may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your healthcare provider may decrease your dose of CRESTOR.oIncrease in blood sugar (glucose) levels. CRESTOR may cause an increase in your blood sugar levels.The most common side effects may include headache, nausea, muscle aches and pains, weakness, and constipation.Tell your healthcare provider if you have any side effect that bothers you or that does not go away.For more information, ask your healthcare provider or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should store CRESTORoStore CRESTOR at room temperature, between 68F to 77F (20C to 25C) and in dry place.Keep CRESTOR and all medicines out of the reach of children.General Information about the safe and effective use of CRESTORMedicines are sometimes prescribed for purposes other than those listed in Patient Information leaflet. Do not use CRESTOR for condition for which it was not prescribed. Do not give CRESTOR to other people, even if they have the same medical condition you have. It may harm them.You can ask your pharmacist or healthcare provider for information about CRESTOR that is written for health professionals.What are the Ingredients in CRESTORActive Ingredient: rosuvastatin as rosuvastatin calciumInactive Ingredients: crospovidone NF, hypromellose NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, red ferric oxide NF, titanium dioxide USP, triacetin NF, tribasic calcium phosphate NF and yellow ferric oxide.CRESTOR(R) is trademark of the AstraZeneca group of companies.(C) AstraZeneca 2026Licensed from SHIONOGI CO., LTD., Osaka, JapanDistributed by:AstraZeneca Pharmaceuticals LPWilmington, DE 19850For more information, go to the CRESTOR website at www.crestor.com or call 1-800-CRESTORThis Patient Information has been approved by the U.S. Food and Drug Administration Revised 04/2026. oCRESTOR is used:to reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or the need for procedures to improve blood flow to the heart called arterial revascularization, in adults at increased risk for these events.along with diet and exercise to lower the level of low-density lipoprotein (LDL-C) cholesterol or bad cholesterol:in adults with primary hypercholesterolemia.and slow the buildup of fatty deposits (plaque) in the walls of blood vessels in adults.in adults and children years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of LDL-C).in adults and children years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C). along with diet for the treatment of adults with:primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat).hypertriglyceridemia.. to reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or the need for procedures to improve blood flow to the heart called arterial revascularization, in adults at increased risk for these events.. along with diet and exercise to lower the level of low-density lipoprotein (LDL-C) cholesterol or bad cholesterol:in adults with primary hypercholesterolemia.and slow the buildup of fatty deposits (plaque) in the walls of blood vessels in adults.in adults and children years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of LDL-C).in adults and children years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C). in adults with primary hypercholesterolemia.. and slow the buildup of fatty deposits (plaque) in the walls of blood vessels in adults.. in adults and children years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of LDL-C).. in adults and children years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C).. along with diet for the treatment of adults with:primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat).hypertriglyceridemia.. primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat).. hypertriglyceridemia.. ohave liver problems.. oare allergic to rosuvastatin or any of the ingredients in CRESTOR. See the end of this leaflet for complete list of ingredients in CRESTOR.. ohave unexplained muscle aches or weakness.. ohave or have had kidney problems.. ohave or have had liver problems.. odrink more than glasses of alcohol daily.. ohave thyroid problems.. oare of Asian descent.. oare pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking CRESTOR, call your healthcare provider right away to discuss your CRESTOR treatment.. oare breastfeeding. CRESTOR can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take CRESTOR. Do not breastfeed while taking CRESTOR.. ocoumarin anticoagulants (medicines that prevent blood clots, such as warfarin). oantacids (medicines you take for heartburn that contain aluminum and magnesium hydroxide. ocyclosporine (a medicine for your immune system). oteriflunomide (a medicine used to treat relapsing remitting multiple sclerosis). oenasidenib (a medicine used to treat acute myeloid leukemia). ocapmatinib (a medicine for the treatment of non-small cell lung cancer). ofostamatinib (a medicine used to treat low platelet counts) ofebuxostat (a medicine used to treat and prevent high blood levels of uric acid) ogemfibrozil (a fibric acid medicine for lowering cholesterol). otafamidis [used to treat cardiomyopathy (enlarged and thickened heart muscle)]. oanti-viral medicines including certain HIV or hepatitis virus drugs such as:lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevircombination ofsofosbuvir/velpatasvir/voxilaprevirdasabuvir/ombitasvir/paritaprevir/ritonavirelbasvir/grazoprevirsofosbuvir/velpatasvirglecaprevir/pibrentasvir andall other combinations with ledipasvir including ledipasvir/sofosbuvir lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir. combination ofsofosbuvir/velpatasvir/voxilaprevirdasabuvir/ombitasvir/paritaprevir/ritonavirelbasvir/grazoprevirsofosbuvir/velpatasvirglecaprevir/pibrentasvir and. sofosbuvir/velpatasvir/voxilaprevir. dasabuvir/ombitasvir/paritaprevir/ritonavir. elbasvir/grazoprevir. sofosbuvir/velpatasvir. glecaprevir/pibrentasvir and. all other combinations with ledipasvir including ledipasvir/sofosbuvir odarolutamide (a medicine for the treatment of prostate cancer). oregorafenib (a medicine used to treat cancer of the colon and rectum). ofibric acid derivatives (such as fenofibrate). oticagrelor (helps reduce the chance of blood clot formation that can block blood vessel). oniacin or nicotinic acid. ocolchicine (a medicine used to treat gout). obelumosudil (used to treat chronic graft-versus-host disease). omomelotinib (used to treat myelofibrosis, rare form of blood cancer). oTake CRESTOR exactly as your healthcare provider tells you to take it.. oTake CRESTOR, by mouth, time each day, with or without food. Swallow the tablet whole.. oCRESTOR can be taken at any time of day, with or without food.. oDo not change your dose or stop CRESTOR without talking to your healthcare provider, even if you are feeling well.. oYour healthcare provider may do blood tests to check your cholesterol levels before and during your treatment with CRESTOR. Your healthcare provider may change your dose of CRESTOR if needed.. oWhile taking CRESTOR, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to.. oIf you take medicine called an antacid that contains combination of aluminum and magnesium hydroxide, take CRESTOR at least hours before you take the antacid.. oIf you miss dose of CRESTOR, take your next dose at your normal scheduled time. Do not take an extra dose of CRESTOR.. oIn case of an overdose, get medical help or contact live Poison Center expert right away at 1-800-222-1222. Advice is also available online at poisonhelp.org.. oMuscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your healthcare provider right away if:you have unexplained muscle pain, tenderness, or weakness, especially if you have fever or feel more tired than usual, while you take CRESTOR.you have muscle problems that do not go away even after your healthcare provider has told you to stop taking CRESTOR. Your healthcare provider may do further tests to diagnose the cause of your muscle problems. you have unexplained muscle pain, tenderness, or weakness, especially if you have fever or feel more tired than usual, while you take CRESTOR.. you have muscle problems that do not go away even after your healthcare provider has told you to stop taking CRESTOR. Your healthcare provider may do further tests to diagnose the cause of your muscle problems.. are taking certain other medicines while you take CRESTOR (see Especially tell your healthcare provider if you take)are 65 years of age or olderare of Asian descenthave thyroid problems (hypothyroidism) that are not controlledhave kidney problemsare taking higher doses of CRESTOR. are taking certain other medicines while you take CRESTOR (see Especially tell your healthcare provider if you take). are 65 years of age or older. are of Asian descent. have thyroid problems (hypothyroidism) that are not controlled. have kidney problems. are taking higher doses of CRESTOR. oLiver problems. Your healthcare provider may do blood tests to check your liver before you start taking CRESTOR and if you have symptoms of liver problems while you take CRESTOR. Call your healthcare provider right away if you have any of the following symptoms of liver problems:feel unusually tired or weakloss of appetiteupper belly paindark urineyellowing of your skin or the whites of your eyes feel unusually tired or weak. loss of appetite. upper belly pain. dark urine. yellowing of your skin or the whites of your eyes. oProtein and blood in the urine. CRESTOR may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your healthcare provider may decrease your dose of CRESTOR.. oIncrease in blood sugar (glucose) levels. CRESTOR may cause an increase in your blood sugar levels.. oStore CRESTOR at room temperature, between 68F to 77F (20C to 25C) and in dry place.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS oPregnancy: May cause fetal harm. (8.1)oLactation: Breastfeeding not recommended during treatment with CRESTOR. (8.2). oPregnancy: May cause fetal harm. (8.1). oLactation: Breastfeeding not recommended during treatment with CRESTOR. (8.2). 8.1 Pregnancy Risk SummaryDiscontinue CRESTOR when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient.CRESTOR decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, CRESTOR may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)]. In addition, treatment of hypercholesterolemia is not generally necessary during pregnancy. Atherosclerosis is chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia for most patients.Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with CRESTOR use in pregnant women are insufficient to determine if there is drug-associated risk of miscarriage (see Data).In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m2), respectively (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.DataHuman DataA Medicaid cohort linkage study of 1,152 statin-exposed pregnant women compared to 886,996 controls did not find significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of statin, and lack of information on non-live births.Animal DataIn female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD of 40 mg/day based on AUC).In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area).In pregnant rabbits given 0.3, 1, and mg/kg/day of rosuvastatin from gestation day to day 18, decreased fetal viability and maternal mortality was observed at mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after single oral gavage dose of mg/kg on gestation day 18.. 8.2 Lactation Risk SummaryLimited data from case reports in published literature indicate that CRESTOR is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Statins, including CRESTOR, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant.Because of the potential for serious adverse reactions in breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with CRESTOR [see Use in Specific Populations (8.1) and Clinical Pharmacology (12.1)].. 8.4 Pediatric Use The safety and effectiveness of CRESTOR as an adjunct to diet to reduce LDL-C have been established in pediatric patients years of age and older with HeFH. Use of CRESTOR for this indication is based on one 12-week controlled trial with 40-week open-label extension period in 176 pediatric patients 10 years of age and older with HeFH and one 2-year open-label, uncontrolled trial in 175 pediatric patients years of age and older with HeFH [see Clinical Studies (14)]. In the 1-year trial with 12-week controlled phase, there was no detectable effect of CRESTOR on growth, weight, BMI (body mass index), or sexual maturation in patients aged 10 to 17 years.The safety and effectiveness of CRESTOR as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established in pediatric patients years of age and older with HoFH. Use of CRESTOR for this indication is based on randomized, placebo-controlled, cross-over study in 14 pediatric patients years of age and older with HoFH [see Clinical Studies (14)].The safety and effectiveness of CRESTOR have not been established in pediatric patients younger than years of age with HeFH, younger than years of age with HoFH, or in pediatric patients with other types of hypercholesterolemia (other than HeFH or HoFH).. 8.5 Geriatric Use Of the 10,275 patients in clinical studies with CRESTOR, 3,159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.Advanced age (>=65 years) is risk factor for CRESTOR-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving CRESTOR for the increased risk of myopathy [see Warnings and Precautions (5.1)].. 8.6 Renal Impairment Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr >=30 mL/min/1.73 m2). Exposure to rosuvastatin is increased to clinically significant extent in patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) who are not receiving hemodialysis [see Clinical Pharmacology (12.3)].Renal impairment is risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. In patients with severe renal impairment not on hemodialysis, the recommended starting dosage is mg daily and should not exceed 10 mg daily [see Dosage and Administration (2.5) and Warnings and Precautions (5.1)].. 8.7 Hepatic Impairment CRESTOR is contraindicated in patients with acute liver failure or decompensated cirrhosis. Chronic alcohol liver disease is known to increase rosuvastatin exposure. Patients who consume substantial quantities of alcohol and/or have history of liver disease may be at increased risk for hepatic injury [see Contraindications (4), Warning and Precautions (5.3) and Clinical Pharmacology (12.3)].. 8.8 Asian Patients Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects when compared with White controls. Adjust the CRESTOR dosage in Asian patients [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS oMyopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher CRESTOR dosage. Asian patients may be at higher risk for myopathy. Discontinue CRESTOR if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue CRESTOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing CRESTOR dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (5.1)oImmune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. Discontinue CRESTOR if IMNM is suspected. (5.2)oHepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue CRESTOR. (5.3). oMyopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher CRESTOR dosage. Asian patients may be at higher risk for myopathy. Discontinue CRESTOR if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue CRESTOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing CRESTOR dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (5.1). oImmune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. Discontinue CRESTOR if IMNM is suspected. (5.2). oHepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue CRESTOR. (5.3). 5.1 Myopathy and Rhabdomyolysis. CRESTOR may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as result of rhabdomyolysis with statins, including CRESTOR.Risk Factors for MyopathyRisk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher CRESTOR dosage. Asian patients on CRESTOR may be at higher risk for myopathy [see Drug Interactions (7.1) and Use in Specific Populations (8.8)]. The myopathy risk is greater in patients taking CRESTOR 40 mg daily compared with lower CRESTOR dosages.Steps to Prevent or Reduce the Risk of Myopathy and RhabdomyolysisThe concomitant use of CRESTOR with cyclosporine or gemfibrozil is not recommended. CRESTOR dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [see Dosage and Administration (2.6)]. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)].Discontinue CRESTOR if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if CRESTOR is discontinued. Temporarily discontinue CRESTOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the CRESTOR dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.. 5.2 Immune-Mediated Necrotizing Myopathy There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue CRESTOR if IMNM is suspected.. 5.3 Hepatic Dysfunction. Increases in serum transaminases have been reported with use of CRESTOR [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after brief interruption in therapy. In pooled analysis of placebo-controlled trials, increases in serum transaminases to more than three times the ULN occurred in 1.1% of patients taking CRESTOR versus 0.5% of patients treated with placebo. Marked persistent increases of hepatic transaminases have also occurred with CRESTOR. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including CRESTOR.Patients who consume substantial quantities of alcohol and/or have history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations (8.7)].Consider liver enzyme testing before CRESTOR initiation and when clinically indicated thereafter. CRESTOR is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue CRESTOR.. 5.4 Proteinuria and Hematuria. In the CRESTOR clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed among CRESTOR treated patients. These findings were more frequent in patients taking CRESTOR 40 mg, when compared to lower doses of CRESTOR or comparator statins, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, consider dose reduction for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.. 5.5 Increases in HbA1c and Fasting Serum Glucose Levels. Increases in HbA1c and fasting serum glucose levels have been reported with statins, including CRESTOR. Based on clinical trial data with CRESTOR, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus [see Adverse Reactions (6.1)]. Optimize lifestyle measures, including regular exercise, maintaining healthy body weight, and making healthy food choices.